Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276; HKG: 1276) announced that its investigational drugs HRS-2189 and HRS-8046 have received Clinical Trial Approvals from China’s National Medical Products Administration (NMPA) – advancing a novel KAT6 inhibitor into a new combination setting and an innovative KRAS G12D‑targeting candidate into the clinic.
Regulatory Milestone
| Item | Detail |
|---|---|
| Agency | NMPA (China) |
| Approval Type | Clinical Trial Approvals (IND) |
| Products | HRS-2189 (KAT6 inhibitor); HRS-8046 (KRAS G12D inhibitor) |
| Indications | HRS-2189: advanced prostate cancer, in combination with novel endocrine therapy; HRS-8046: solid tumors harboring the KRAS G12D mutation |
| Approval Date | 28 Oct 2026 |
| Next Steps | Initiation of clinical trials; timelines not disclosed |
Drug Profile & Mechanism of Action
- HRS-2189 – Molecule: A novel KAT6 inhibitor that exerts anti‑tumor effects by suppressing histone lysine acetylation and regulating the expression of multiple downstream oncogenes.
- HRS-2189 – First‑in‑Class Potential: Currently, no drugs targeting the same pathway have been approved for marketing globally or domestically, positioning HRS-2189 in a clinically unvalidated but differentiated epigenetic space.
- HRS-2189 – Program History: Previously approved for a clinical trial in combination with HRS-6209 for breast cancer; the newly approved indication is its combination with novel endocrine therapy in advanced prostate cancer – expanding the asset across hormone‑driven tumor types.
- HRS-8046 – Molecule: An innovative anti‑tumor drug independently developed by Hengrui, intended for the treatment of solid tumors harboring the KRAS G12D mutation.
- HRS-8046 – Target: KRAS G12D, one of the most prevalent and historically “undruggable” oncogenic driver mutations, frequently found in pancreatic, colorectal, and other solid tumors.
Clinical Development Status
| Asset | Approved Setting | Prior Approvals | Clinical Data |
|---|---|---|---|
| HRS-2189 | Advanced prostate cancer, with novel endocrine therapy | Combination with HRS-6209 in breast cancer | Not disclosed |
| HRS-8046 | KRAS G12D‑mutant solid tumors | First clinical trial approval | Not disclosed |
Trial designs, sample sizes, and development timelines were not disclosed in the announcement.
Market Impact & Outlook
- Oncology Franchise Depth: The dual approvals extend Hengrui’s industry‑leading oncology pipeline into two high‑value frontier areas – epigenetic therapy (KAT6) and targeted KRAS inhibition – reinforcing its R&D engine among Chinese innovative drugmakers.
- Prostate Cancer Landscape: Advanced prostate cancer patients progressing on existing endocrine therapy face limited options; a KAT6 inhibitor combined with novel endocrine therapy represents a mechanistically distinct strategy to delay or overcome resistance.
- KRAS G12D Opportunity: G12D is among the most common KRAS mutations with high unmet need across pancreatic and colorectal cancers; competition in this class is intensifying globally, and an independently developed Chinese asset adds to Hengrui’s differentiation.
- Commercial Outlook: As early‑stage clinical assets, revenue contribution depends on trial outcomes and future regulatory review; no forecasts were disclosed.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for HRS-2189 and HRS-8046. Actual results may differ due to risks including clinical trial execution, safety findings, subsequent regulatory review requirements, and competitive dynamics in oncology drug development.-Fineline Info & Tech
